Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Do you discontinue an aromatase inhibitor in a patient if they have a cardiac event while on the drug?
Does the presence of other cardiac risk factors change your recommendation?
Related Questions
How long would you recommend a woman with HR+ node-positive breast cancer treated with surgery and chemotherapy during pregnancy can breastfeed, prior to starting adjuvant endocrine therapy?
How would you treat rapidly growing inflammatory breast cancer, invasive lobular triple negative subtype, after two cycles of neoadjuvant keynote 522?
What would be your treatment approach in a premenopausal BRCA2+ patient with ER negative (repeated twice), PR positive (30%, variable staining, weak to high), HER2 negative breast cancer, cT2N0, grade 2-3?
Would you give adjuvant chemotherapy to a premenopausal female who underwent bilateral mastectomies for ER+ pT2N1 disease, grade 1, with low oncotype (5)?
In which patients do you offer adjuvant bisphosphates in breast cancer treatment?
Would you offer neoadjuvant chemoimmunotherapy per KEYNOTE 522 for a patient with clinical stage IIB triple-negative breast cancer with apocrine histology or recommend surgery first?
What would you recommend regarding IVF in a patient with DCIS on tamoxifen dealing with infertility?”
How do you decide between neoadjuvant chemotherapy vs neoadjuvant endocrine treatment in postmenopausal women with node involvement?
What are your top takeaways from SABCS 2023?
Would you consider HRT after risk-reducing salpingo-oophorectomy for a young (mid-30s) patient with BRCA1 and a history of TNBC?